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ABSTRACT 
 
 
 Mammalian artificial chromosomes, or MACs, have been studied as a potential 
avenue for hosting large numbers of transgenes in mammalian cells. MACs have several 
advantages over viral-based methods for transgene expression, including a lack of limits 
on loading capacity, which bypasses issues associated with integration into the genome. 
One area of research in which MACs can be applied is the biomanufacturing of protein-
based therapeutics, where reported genome instability in Chinese hamster ovary (CHO) 
cells can lead to reduced product titer. MACs can potentially aid in solving this issue by 
providing alternate hosting sites for transgenes for integration of protein-based 
therapeutic production. However, some hurdles exist in the path of utilizing MACs as a 
biology tool, including the acquisition of sufficient mass and concentration of a MAC, 
the molecular cloning of a transgene into a MAC, and delivery of the cloned MAC to 
target mammalian cells. To address this, improvements were made at the steps of 
transformation of the MAC into E. coli, isolation of positive colonies, and subsequent kit 
purification to generate sufficient masses and concentrations for downstream 
applications. Using Gibson Assembly, a selectable marker, glutamine synthetase (GS), 
was successfully cloned onto the MAC, yielding the construct MAC-GS. MAC-GS was 
subsequently electroporated into suspension CHO cells, and selection by removal of L-
glutamine demonstrated the functionality of GS. These results represent a positive step 
forward for the implementation of MACs as a useful synthetic biology tool. 
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CHAPTER ONE 
 
INTRODUCTION 
 
Synthetic biology represents the intersection of biology and engineering: 
designing and constructing circuits and networks of multiple transgenes in order to 
achieve various objectives, such as producing therapeutics or probing cellular biology in 
ways that other subfields of biology cannot. The ability to synthesize these transgene 
circuits has become easier and easier, as the cost of directly synthesizing DNA has fallen 
further and further. However, these circuits have zero use if the genes cannot be delivered 
to the target organisms in order to be used, and this delivery of multiple transgenes, 
especially into mammalian cells, remains a major hurdle for carrying out synthetic 
biology (Martella et al., 2016; Rennekamp, 2018). 
An example of such a construct that is of interest in synthetic biology is the 
mammalian artificial chromosome (MAC). Also referred to in the literature as a human 
artificial chromosomes (HAC), MACs have been studied as a potential avenue for 
hosting large numbers of transgenes in mammalian cells. As the name implies, MACs are 
non-endogenous to a mammalian cell but contain elements recognizable by the cell for 
the purposes of DNA propagation through mitosis, like the centromere. MACs exhibit 
some features that are desirable for the purposes of synthetic biology. A MAC serves as a 
site for hosting transgenes that does not interfere with the function of the endogenous 
genome. Current viral vector-based methods for delivering transgenes to mammalian 
cells integrate them into the genome randomly and in locations that are accessed to 
different degrees by transcriptional machinery. Known as the ‘position effect,’ this 
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phenomenon may adversely affect transgene expression as a result. In contrast, a MAC 
serves as a well-defined, stable environment for hosting transgenes (Martella et al., 
2016). 
However, some challenges present in regards to utilization of MACs in synthetic 
biology. Acquiring enough of the MAC to carry out downstream processes is difficult: 
conventional plasmid preparation kits exhibit difficulties in extracting plasmids larger 
than 10 – 20 kb. Molecular cloning of transgenes onto a MAC is also a non-trivial 
challenge; site-specific recombination, while widely used in the literature, is limited in 
regards to cloning of multiple transgenes, and more conventional methods like restriction 
enzyme cloning or Gibson Assembly have not been extensively used in the literature. 
Furthermore, as previously mentioned, delivery of the MAC to mammalian cells is a 
significant roadblock for utilizing it in synthetic biology. 
One such area that MACs could potentially address problems in is 
biomanufacturing of recombinant protein-based therapeutics, such as monoclonal 
antibodies (mAbs). The market for such therapeutics is large; world-wide sales of mAbs 
projected to reach $125 billion by 2020 (Ecker et al., 2015). Chinese hamster ovary 
(CHO) cells are the cell line most commonly used to produce protein-based therapeutics; 
70% of those sales constitute therapeutics that were produced in CHO cells (Kunert and 
Reinhart, 2016). However, loss of mAb titer has been observed over time in CHO cell 
cultures, even with selection pressure. This loss is attributed to genomic instability 
resulting from rearrangement of genomic elements (Kunert and Reinhart, 2016; Wurm 
and Wurm, 2017). MACs can potentially offer a solution to this problem; hosting 
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transgenes on a separate chromosome with no known transposable elements that the CHO 
cell can recognize for sequence rearrangement. This would allow the CHO cell to 
maintain intact transgene cassettes inside the nucleus and thus retain acceptable protein 
titer for biomanufacturing purposes over the length of 60 generations, a typical duration 
for assessing clonal stability of transgenes in CHO cell cultures (Capella Roca et al., 
2019). 
This project was divided into three challenges in the expression of MACs in CHO 
cells: 1) obtaining sufficient MAC material for the delivery to CHO cells; 2) molecular 
cloning a reporter transgene into the MAC; and 3) delivering the cloned MAC to CHO 
cells. Currently, MACs are produced in E. coli, and the purification steps do not achieve 
high yields, due to the construct’s large size, low copy number, and instability of its 
centromeric repeats. Inserting transgenes into the MAC has typically been performed 
with site-specific recombination. However, using site-specific recombination to insert 
multiple transgenes into the MAC has some drawbacks, such as a lack of flexibility and 
cumbersome implementation. Delivery of the MAC into suspension CHO cells has not 
been extensively explored previously in the literature, so finding a suitable method of 
delivery was necessary. 
As a summary of this thesis, Chapter 2 provides some background on the various 
aspects of this project and a brief review of literature directly relevant to this project, with 
a particular focus on MACs themselves, CHO cells, and various gene delivery methods. 
Chapter 3 addresses the efforts to obtain the MAC in high yield and purity, including 
transformation into E. coli; modifications of plasmid preparation procedure; and various 
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methods of verification and characterization of the MACs post-purification. Chapter 4 
addresses molecular cloning of a transgene, including Gibson Assembly of the transgene 
into the MAC and subsequent verification of the sequence and size. Chapter 5 describes 
the studies to deliver the MAC to mammalian cells, including studies of electroporation 
of CHOZN GS-/- with a positive control construct and the MAC loaded with a transgene 
as well as subsequent assessment of the electroporation results. Chapter VI summarizes 
the results of the project and future directions for the project. The appendix contains 
studies of histone-mediated transfection as a delivery method, including expression and 
purification of histones for HMT; pilot HMT studies in HEK 293 cells with HMT; and 
subsequent transfection studies with HMT and electroporation in CHOZN GS-/-. 
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CHAPTER TWO 
 
BACKGROUND AND SELECTED LITERATURE REVIEW 
 
This chapter details pertinent background and a review of selected literature about 
various topics: MACs themselves, the different types that exist, and the rationale behind 
choosing a particular type of MAC to work with; CHO cells as they pertain to the 
recombinant protein industry and their particular characteristics; and various methods 
used for transgene delivery to mammalian cells. 
2.1 What Are MACs? 
A mammalian artificial chromosome (MAC), as the name implies, is a DNA 
construct that is constructed synthetically and not the same as one of the constituent 
chromosomes of a mammalian cell. It contains a centromere, which allows the cell to 
split copies properly among daughter cells during mitosis. Because of this property, 
MACs have been considered as a promising way to host genes within a mammalian cell 
without some of the drawbacks of current methods for integrating transgenes into a cell’s 
genome (Kouprina et al., 2018). 
Three types of artificial chromosomes exist in the literature: ‘top-down’ artificial 
chromosomes, ‘bottom-up’ (or de novo) artificial chromosomes, and satellite-DNA-based 
artificial chromosomes (SATACs). 
2.1.1 ‘Top-Down’ MACs 
“Top-down” formation of a MAC involves removing endogeneous genes from 
existing chromosomes that are already inside of a cell in order to isolate the centromere, 
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before inserting transgenes of interest, usually through site-specific recombination (SSR) 
techniques. Figure 2.1 shows this process. Endogenous genes were broken off by 
telomere-associated chromosome fragmentation (TACF), in which cells were transfected 
with plasmids that contained telomere sequences and were targeted to a particular 
chromosome. Through homologous recombination, that chromosome’s endogenous 
genes were swapped out with the telomeric plasmids, thus generating a miniature 
chromosome of telomeres, a centromere, and SSR acceptor sites (Farr et al., 1992; Farr et 
al., 1995; Kazuki et al., 2011; Vollrath et al., 1988). 
 
 
Figure 2.1. Visual interpretation of the creation of ‘top-down’ artificial chromosomes. Taken from Kazuki 
et al., 2011; image licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 
3.0 Unported License: http://creativecommons.org/licenses/by-nc-nd/3.0/. 
 
2.1.2 ‘Bottom-Up’ MACs 
 ‘Bottom-up’ formation of a MAC relies on the fact that the centromere of a 
human chromosome consists of repeats of non-coding DNA, termed ‘satellite DNA.’ 
Alpha-satellite (or alphoid) DNA, the most common type of satellite DNA, consists of 
repeats of a 171 bp sequence arranged in a head-to-tail tandem repeat array. These arrays 
are organized further into higher-order repeats in order to form a functional centromere 
(Kouprina et al., 2018; Molina et al., 2017). 
Previous groups constructed bottom-up MACs by making copies of these alphoid 
sequences through rolling-circle amplification (RCA). These longer fragments were 
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assembled into a target vector in S. cerevisiae through transformation-associated 
recombination (TAR). The process of TAR involves transforming linear fragments with 
homologous sequences at their ends and having S. cerevisiae cells join the fragments into 
a single construct (Kouprina and Larionov, 2008). This process yielded a partially-
formed MAC of ~60 kb that can be transfected into mammalian cells by lipofectamine or 
other methods (Ebersole et al., 2005). 
Once the partially-formed MAC was transfected into mammalian cells, the cells 
recognized the presence of centromeric DNA and synthesized centromeric protein A 
(CENP-A). Interactions with the centromere protein B (CENP-B) box, an operator 
sequence for CENP-B, helped to establish chromatin formation and amplify the existing 
centromeric repeats to form a fully functional MAC (Okamoto et al., 2007). An SSR 
acceptor site was inserted via homologous recombination for gene delivery purposes 
(Kouprina et al., 2018). 
A newer version of the bottom-up MAC, the alphoidtetO MAC, incorporates the 
tetracycline operator (tetO) into alphoid DNA sequences for conditional inactivation 
when the tetracycline repressor protein is present (Nakano et al., 2008). Figure 2.3 shows 
the process by which the alphoidtetO MAC was constructed. 
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Figure 2.2. Visual depiction of the process by which the alphoidtetO MAC was constructed. Taken from 
Kouprina et al., 2018 and reproduced with permission. 
 
2.1.3 Satellite-DNA-based Artificial Chromosomes (SATACs) 
SATACs are MACs that contains elements of both top-down and bottom-up 
construction (Lindenbaum et al., 2004; Katona, 2015). Foreign DNA is integrated into 
ribosomal RNA gene sites on existing chromosomes, which induces large-scale 
amplification of the p arms. During this large scale amplification of the p arms, the 
centromere can be duplicated. When cell division occurs, a chromosome with a duplicate 
centromere undergoes breakage in the region between the two centromeres, producing a 
SATAC. 
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Figure 2.3. The process of generating a SATAC. Taken from Katona, 2015, and reproduced with 
permission. 
 
The SATAC was the basis for the Artificial Chromosome Expression (ACE) 
System, an attempt to establish a MAC-based platform to host transgenes in order to 
produce recombinant proteins. As seen in Figure 2.5, the ACE System, as a whole, has 
three components: the Platform ACE, a SATAC with a promoter, an SSR acceptor site 
(attP), and a selectable marker for resistance to an antibiotic (puromycin). The ACE 
Integrase is a lambda integrase that has a point mutation to remove the requirement for 
host co-factors. The ACE Targeting Vector has an SSR donor site (attB), the transgene 
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cassette, and a promoterless selectable marker. The recombination reaction places the 
ACE Targeting Vector’s selectable marker downstream of the Platform ACE’s promoter; 
thus, the Loaded ACE has a new selectable marker that can be used for subsequent 
selection to verify a successful recombination (Lindenbaum et al., 2004; Tóth et al, 
2013). 
 
 
Figure 2.4. A diagram of how the ACE System works. From Tóth et al., 2013; image licensed under a 
Creative Commons Attribution 4.0 International License: https://creativecommons.org/licenses/by/4.0/ 
 
2.1.4 Summary 
The three different types of MACs all have interesting properties. Top-down 
MACs are retrofitted chromosomes; the existing genes on a chromosome are removed to 
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isolate the centromere so that new genes can be inserted. In that way, they are very 
different from bottom-up chromosomes, which are built de novo and assembled piece by 
piece. SATACs have elements of both top-down and bottom-up construction, in that they 
are derived from existing chromosomes but exhibit elements of de novo construction in 
how DNA sequences are amplified. 
2.2 Chinese Hamster Ovary (CHO) Cells 
2.2.1 CHO Cell Types as Related to the Biotechnology Industry 
Many different CHO cell lines exist, some with useful genetic modifications. 
CHO-K1 is a clone of the original CHO line derived from Theodore Puck’s laboratory, 
from which many of these other CHO lines were derived (Wurm and Wurm, 2017). 
CHO-DXB11 was derived in 1980 from mutagenization of CHO-K1 cells with ethyl 
methanesulfonate, which deleted one locus of the gene for dihydrofolate reductase 
(DHFR) and generated a missense mutation in the other locus, thus making a DHFR+/- 
variant (Urlaub and Chasin, 1980). CHO-DG44 was a later attempt at generating a 
DHFR-/- variant that utilized gamma radiation to delete both alleles, as some CHO-
DXB11 cells demonstrated the ability to revert to the DHFR+/+ phenotype (Urlaub et al., 
1983). This mutation really opened the door for usage of CHO cells in bioprocessing; 
Genentech succeeded in producing tissue plasminogen activator in CHO cells, and the 
strategy used therein served as a model for the entire industry as a whole (Wurm and 
Hacker, 2011). 
Auxotrophic selection for CHO cells typically revolves around the genes that 
code for two enzymes required for anabolism in CHO cells: DHFR and glutamine 
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synthetase (GS). DHFR converts dihydrofolate to tetrahydrofolate, which is an important 
cofactor in the biosynthesis of purines and thymidine (Urlaub and Chasin, 1980). With 
DHFR knocked out, or with DHFR inhibited by methotrexate (MTX), CHO cells require 
glycine, hypoxanthine, and thymidine in the medium or a functional copy of DHFR in 
order to grow (Wuest et al., 2012). GS ligates ammonia to L-glutamate to form L-
glutamine and is the biosynthetic pathway for L-glutamine in CHO cells. With GS 
knocked out, or with GS inhibited by methionine sulfoximine (MSX), CHO cells require 
either L-glutamine or a functional copy of GS in order to grow (“CHOZN® Platform 
Technical Bulletin”). 
2.2.2 The CHOZN® GS-/- Cell Line 
Developed by Sigma Aldrich Fine Chemicals (SAFC), the CHOZN® GS-/- cell 
line was derived from a CHO-K1 adherent cell line that was adapted to suspension 
growth. Zinc finger nucleases were then used to alter a section of exon 6 of GS. Exon 6 
corresponds to the substrate-binding domain of GS, in order to render the protein non-
functional. This made the CHO cells into glutamine auxotrophs. L-glutamine removal is a 
common route of selection in the biopharmaceutical industry because it is unstable at 
physiological pH in liquid cell culture medium and is thus usually added at time of use. 
Implementing L-glutamine selection is rather easy as a result, since addition of it is 
already a separate step in medium preparation. MSX selection is undesirable because it is 
toxic, it is an additional chemical that adds on cost to a bioprocess, and it requires 
subsequent removal during downstream purification. Knocking out GS sidesteps all of the 
issues associated with MSX selection (“CHOZN® Platform Technical Bulletin”). 
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2.3 Current Transgene Delivery Methods 
Existing methods in the literature for delivering genes to mammalian cells include 
cationic lipids, electroporation, microcell-mediated chromosome transfer (MMCT), 
polyethylene glycol (PEG)-mediated cell fusion, and histone-mediated transfection 
(HMT). 
2.3.1 Cationic Lipids 
Cationic lipid transfection has been widely used to transfect mammalian cells, 
especially of the adherent variety. The basic procedure involves three steps. First, the 
cationic lipid molecule interacts with the negatively-charged backbone of the DNA 
payload, forming an electrostatic complex. That complex then interacts further with the 
negatively-charged phospholipid membrane of the cell, entering it through an endocytotic 
pathway. The DNA payload then disengages from the cationic lipid and diffuses through 
the cytoplasm to the nucleus for gene expression (Chesnoy and Huang, 2000). 
While cationic lipid transfection works fairly well for adherent cell lines, 
transfection efficiency is not as high for suspension cells. One given reason for this is that 
the cationic lipid complex does not attach to the surface of suspension cells very well, 
leading to less uptake of the lipid complexes (Basiouni et al, 2018). 
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Figure 2.5. Flow diagram of the mechanism of action of cationic lipid transfection. Taken from Srinivas et 
al., 2009, and reproduced with permission. 
 
2.3.2 Electroporation 
Electroporation is another widely-used method for delivering genes to 
mammalian cells. As the name implies, electroporation involves subjecting cells to a 
strong electric field. The basic procedure of electroporation involves mixing cells with a 
DNA payload in suspension and loading the mix into a special cuvette that contains metal 
plates. The cuvette and content are then subjected to a high voltage. The prevailing notion 
is that the electric field weakens the cell membrane and creates pores, allowing DNA to 
diffuse into the cell. However, much about electroporation’s mechanism of action is up 
for debate (Escoffre et al., 2008). 
One of the disadvantages of electroporation is the low resultant cell viability; 
altering a cell’s membrane can lead to cell death for many cells (Shigekawa and Dower, 
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1988). Despite low cell viability following electroporation, this method is the preferred 
gene delivery method for the CHOZN GS-/- cell line (“CHOZN® Platform Technical 
Bulletin”). 
2.3.3 Microcell-mediated Chromosome Transfer (MMCT) 
 In terms of transferring MACs between cells, MMCT is the most commonly used 
method. MMCT involves 1) micronucleation of a donor cell line’s chromosomes, 2) 
separation of micronuclei from the cytoplasm, and 3) fusion with recipient cell lines, as 
shown in Figure 2.7. The first step begins by applying colcemid, a small molecule drug 
that arrests cells in the metaphase by inhibiting formation of the mitotic spindle. By 
inhibiting mitosis for long enough, nuclear envelopes will form around the individual 
chromosomes of the cell, creating micronuclei that contain between one and a few 
chromosomes inside of each cell. These micronuclei are important in order to isolate 
chromosomes. To separate the micronuclei from the cytoplasm, cells are then centrifuged 
at high speeds in the presence of cytochalasin B, which is used to separate the 
micronuclei from the cytoplasm of the cells. The micronuclei are subsequently filtered in 
order to collect micronuclei containing a single chromosome. To fuse the micronuclei 
with other cell lines, various cell fusion methods, including the use of Sendai virus, 
phytohemagglutinin-P (PHA-P), and polyethylene glycol (PEG), are then used to fuse 
micronuclei with recipient cell lines (Ege and Ringertz, 1974; Fournier and Riddle, 1977; 
Meaburn et al. 2005; Hiratsuka et al., 2015; Suzuki et al., 2016). 
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Figure 2.6. Diagram of MMCT. Taken from Meaburn et al., 2005, and reproduced with permission. 
 
MMCT has some disadvantages. One such disadvantage is low efficiency for the 
transfer of micronuclei from donor cells to recipient cells. Another major disadvantage is 
the limited number of donor cell lines that can undergo MMCT. CHO and mouse A9 
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cells are the most commonly used donor lines, CHO and A9 cells undergo repeated 
hyperploidization, creating more chromosomes. This produces many micronuclei, 
increasing the chances of micronuclear fusion success with recipient cell lines 
(Liskovykh et al., 2016). 
2.3.4 Polyethylene glycol (PEG)-mediated Cell Fusion 
The methods for transgene delivery mentioned above are conventional for MACs. 
However, only a limited number of other methods exist in the literature. One novel 
method, described in Brown et al. (2016), used S. cerevisiae as the carrier for large DNA 
molecules by fusing the yeast cells to mammalian cells using polyethylene glycol (PEG) 
and dimethyl sulfoxide (DMSO). TAR was then used to join linear fragments of DNA 
into a yeast centromeric plasmid (YCp), as shown in Figure 2.8. Two fluorescent 
proteins, mCherry and GFP, were utilized with organism-specific promoters to evaluate 
efficiency of cell fusion and expression in mammalian cells, respectively. The flexibility 
of the YCp design via TAR allowed the authors to produce constructs of varying sizes, up 
to 1.1 Mb, which is approximately the size of a fully-formed MAC in a mammalian cell 
and about 18 times bigger than the 60 kb precursor MAC construct. 
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Figure 2.7. Diagram of PEG-mediated cell fusion. Taken from Brown et al., 2016, and reproduced with 
permission. 
 
While this article presented a novel idea for getting around the barriers presented 
by more direct methods of gene delivery, implementing it would be a challenge in a 
bioprocessing context, because fungal contamination is seen as undesirable in 
mammalian cell cultures. Fungi can cause product spoilage by producing unwanted 
byproducts and ruining products, and said unwanted byproducts can also pose health 
hazards (Sandle, 2019). 
2.3.5 Histones and Histone-mediated Transfection (HMT) 
 Histone-mediated transfection as a method for delivering transgenes to cells has 
been a subject of study since the late 1990s. Histones, as the proteins that condense DNA 
into chromatin, have a propensity for binding DNA via electrostatic interactions. 
Histones have also been found to contain nuclear localization signals (NLS), which 
facilitate transport from the cytoplasm to the nucleus. As such, histones have some 
 19
potential as carriers of transgenes. The linker histone (H1), the core histones that make up 
the nucleosome (H2A, H2B, H3, and H4), and other histone-like proteins have been 
explored at length for their propensities for transgene delivery (Han et al., 2019). 
 One such study on HMT explored the capabilities of core histones H2A and H2B 
to transfect mammalian cells in order to deliver transgenes. Fusion proteins were 
constructed from combinations of histone H2B and an NLS from the simian virus 40 
large tumor antigen, with green fluorescent protein (GFP) included. These proteins were 
used as carrier molecules for a DNA construct that expressed a fusion protein, histone 
H2A connected to the fluorescent protein DsRed2. The H2B-containing fusion proteins 
were shown to be capable of delivering the plasmid payload to the nucleus, as measured 
by expression of DsRed2-H2A, with LipofectAMINE 2000 as a positive control. 
Including the NLS on the H2B-GFP fusion protein and histone H2A appeared to have an 
additive effect on the percentage of cells expressing DsRed2-H2A, as seen in Figure 2.9 
(Wagstaff et al., 2007). 
One possible limitation of histone-mediated transfection is that it acts similarly to 
cationic lipids in its mode of action. Like cationic lipids, histones also associate with 
DNA largely through electrostatic interactions. The similarity of the mechanism of action 
for attracting DNA could imply that histones also share the same pitfalls as cationic lipids 
when it comes to transfecting suspension cells. 
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Figure 2.8. Histone-mediated transfection of DsRed2-H2A in HeLa cells. "DNA L" represents the 
LipoFECTAMINE 2000 positive control. Taken from Wagstaff et al., 2007; image licensed under a 
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License: 
https://creativecommons.org/licenses/by-nc-nd/4.0/ 
2.4 Summary 
Chapter 2 covers much of the important background information concerning 
MACs, CHO cells, and gene delivery methods. Three types of MACs exist in the 
literature: top-down chromosomes, in which existing chromosomes have their 
endogenous genes removed in order to isolate the centromere and load new transgenes; 
bottom-up chromosomes, which are constructed de novo and use the target mammalian 
cell’s machinery to build up the centromere; and SATACs, which employ elements of 
both top-down and bottom-up MACs in construction and have been investigated as 
platforms for recombinant protein production. 
A brief history of CHO cells is also covered in Chapter 2; the various strains of 
CHO cells are described along with common methods of selection for the purposes of 
 21
recombinant protein production. Particular attention is paid to the CHOZN GS-/- line, as 
the target cell line for much of the work in this thesis. 
In addition, some transgene delivery methods in use for mammalian cells are 
discussed. Cationic lipid transfection is widely used among adherent cells, but it has 
some efficiency issues with suspension cell lines. Electroporation is also widely used but 
has the side effect of decreased cell viability post-electroporation. MMCT is a technique 
specific to MACs that is commonly used to transfer MACs between mammalian cell 
lines, but it also exhibits efficiency issues along with a limited number of cell lines that 
can support the technique. PEG-mediated cell fusion is interesting, especially in its ability 
to transfer very large DNA constructs, but it has issues when applied to real-world 
situations. HMT has some interesting properties as a transfection agent, like histones’ 
affinities for DNA and nuclear localization properties, and additive effects on transfection 
efficiencies have been shown, but it potentially runs into some of the same drawbacks 
that cationic lipid transfection does because of the similarity in the mechanism of action. 
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CHAPTER THREE 
 
PURIFICATION OF AN ARTIFICIAL CHROMOSOME IN HIGH YIELD 
 
  
The first major challenge to overcome in order to utilize the MAC as a synthetic 
biology tool was to obtain enough of it in high yield for use in downstream applications. 
As mentioned previously, conventional plasmid preparation kits have difficulties with 
isolating plasmids larger than 10 – 20 kb in large quantities, whereas the MAC is sized in 
the area of 60 kb. This chapter describes the MAC itself and its characteristics as well as 
the work conducted to improve the isolation and purification of the MAC. 
3.1 Rationale for Selection of Type of MAC 
When considering whether to utilize top-down or bottom-up MACs for this 
project, the main factor in the decision-making process was how to insert transgenes onto 
the MAC. The majority of groups that have published on MACs use SSR after delivering 
them to cells in order to load transgenes onto MACs, and several groups have published 
on integration of multiple genes onto a MAC (Yamaguchi et al., 2011; Tóth et al., 2014; 
Suzuki et al., 2014; Yoshimura et al., 2015; Lee et al., 2018). However, loading multiple 
transgenes through SSR has some limitations. Efforts to implement sequential integration 
of transgenes onto a MAC have required an iterative implementation that tacks on 
additional time as the number of transgenes increases; simultaneous integration of 
multiple transgenes requires a different integrase for each transgene. Conventional 
cloning methods, like Gibson Assembly, offer more flexibility and less cumbersome 
ways to load multiple transgenes onto a MAC but have not been extensively explored in 
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the literature. Cloning was hypothesized to be easier with bottom-up MACs because they 
are, at some point, purified before delivery to mammalian cells, which offers an 
opportunity to utilize conventional cloning methods in order to introduce transgenes onto 
the MAC. In contrast, top-down MACs and SATACs are constructed and loaded with 
transgenes exclusively inside a cellular environment, ruling out the opportunity to use 
conventional cloning methods for loading transgenes. 
3.2 Transformation of MAC into E. Coli with Electroporation 
As mentioned previously, bottom-up MACs were selected as the MAC for this 
project. A copy of the MAC was donated by Dr. Natalay Kouprina of the National 
Institutes of Health. The MAC, as previously described in Nakano et al. (2008), 
contained an ~50 kb α-satellite DNA cloned into a 10,209 bp vector (referred to in 
Nakano et al. as ‘RCA-Sat43’). This MAC also contained other useful gene cassettes for 
compatibility with different organism types. A sequence map of the MAC with α-satellite 
repeats is shown in Figure 3.1. 
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Figure 3.1. A sequence map of the MAC. Image generated by SnapGene software (from GSL Biotech; 
available at snapgene.com). 
 
RCA-Sat43, shown in Figure 3.2, contains a bacterial artificial chromosome 
(BAC) cassette that includes the sopABC genes and origin of replication (ori2) that allow 
bacteria to partition a plasmid as if it were a chromosome, as well as a selectable marker 
that confers resistance to chloramphenicol (CamR). It also has a yeast artificial 
chromosome cassette (YAC) that includes the CEN6/ARSH4 gene, a fusion of the 
centromere from chromosome VI of S. cerevisiae fused to an autonomously replicating 
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sequence associated with histone H4. These two cassettes were present in order to 
facilitate RCA and TAR, as mentioned in Chapter 2. In addition, a blasticidin resistance 
cassette with an SV40 promoter and poly(A) signal were included, for selection in 
mammalian cells. The α-satellite repeats were inserted at the MluI restriction enzyme site 
during TAR to generate the MAC seen in Figure 3.1. 
 
 
Figure 3.2. A sequence map of RCA-Sat43. Image generated by SnapGene software (from GSL Biotech; 
available at snapgene.com). 
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In order to transform this into E. coli, due to the large size of the DNA construct 
in question, conventional heat shock methods were deemed nonviable for transformation. 
As such, higher-efficiency techniques, like electroporation, were used to deliver the MAC 
to E. coli. 1 ng of the MAC was transformed into 15 µL 10-beta Electrocompetent E. coli 
cells (New England Biolabs) in a 1 mm gap cuvette at 1800 V, 25 µF, and 200 Ω. 
Colonies were subsequently streak-plated onto agar plates containing chloramphenicol 
for selection, and colonies were observed, as seen in Figure 3.3. Of note, the outgrowth 
step and incubation steps were carried out at 30°C instead of 37°C because the array of 
centromeric repeats is unstable, and repeats can be lost during the transformation process 
if carried out at typical conditions. The cells were shaken at lower-than-normal speeds 
during the outgrowth step, as well, for this reason. 
 
 
Figure 3.3. Chloramphenicol-containing agar plate of E. coli DH10β cells transformed with MAC via 
electroporation. 
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Importantly, two key steps following successful transformation were also affected 
by this possibility of losing repeats during transformation. Post-plating, instead of picking 
a single colony, multiple colonies were picked for making glycerol stocks. In addition, 
when growing cultures from glycerol stocks, instead of simply stabbing the glycerol, an 
entire stock would be used for each culture. The idea behind this was to hedge bets on 
how the centromeric repeats were maintained across colonies by selecting multiple 
colonies and using a larger sample size of bacterial colonies in order to recover MAC of 
the correct size. 
3.3 Purification of MAC with PureLink HiPure Plasmid Midiprep Kit 
Once E. coli cells had been successfully transformed with the MAC, extracting 
and purifying it via plasmid preparation was necessary for subsequent characterization 
and molecular cloning. Table 3.1 lists the DNA mass and concentration requirements for 
the molecular cloning and delivery methods used later on. While molecular cloning itself 
did not require high DNA masses and concentrations, delivery did require high amounts 
and concentrations of DNA. 
 
Table 3.1. DNA mass and concentration requirements for molecular cloning and delivery. 
Application DNA Mass Required DNA Concentration Required 
Molecular Cloning 250 ng 50 ng/µL 
Delivery 30 – 50 µg 600 – 1000 ng/µL 
 
Purification of the MAC, however, was a non-trivial challenge. Most kits for 
plasmid preparation have an upper limit on the size of plasmid that can be purified; that 
limit is often in the range of 10 – 20 kb, and yields drop as the size of the plasmid 
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increases. Furthermore, the MAC’s origin of replication for E. coli is derived from the F 
plasmid (Kononenko et al., 2005), which is inherently single-copy in E. coli. 
From Nakano et al. (2008), the Large Construct Kit (QIAGEN) was the kit of 
choice for extracting the MAC from E. coli. The kit itself is technically challenging to 
carry out, though; its associated protocol features two isopropanol extractions, a 1 h 
exonuclease digestion step, and multiple high speed spins of 30 mins to 1 h, all of which 
adds up to a protocol runtime of 7 h or more. Yields from the Large Construct Kit, from a 
500 mL culture, were on the order of 9 µg at a concentration of 45 ng/µL, for 
downstream applications. 
A search of literature on MACs yielded a kit that had been used in another paper 
by Logsdon et al. (2019) to extract MACs from bacteria, the PureLink HiPure Plasmid 
Midiprep Kit (Thermo Fisher Scientific). The kit itself had additional protocol 
modifications for large constructs like bacterial artificial chromosomes (BACs), and it 
required much less culture for extraction (100 mL vs. the Large Construct Kit’s 500 mL). 
Initial midipreps from this kit yielded plasmid masses of around 4 µg at 40 ng/µL, which 
was still not enough to meet the DNA demands of electroporation. 
Subsequent optimization of the stock protocol was carried out to increase yields. 
A table detailing the original protocol (“PureLink™ HiPure Plasmid DNA Purification 
Kits”) and major changes made can be found below, in Table 3.2. 
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Table 3.2. Modifications to the PureLink HiPure Plasmid Midiprep Kit protocol. 
Original Step Modified Step (If 
Changed) 
Reasoning 
Prepare a 20-h bacterial culture 
of 100 mL, grown to an OD600 
of 5.0. 
Grow 100 mL 
bacterial culture to 
OD600 of 0.2 (as 
measured on 
Nanodrop pedestal).  
An OD600 of 0.2 on the 
Nanodrop pedestal roughly 
corresponds to the switch 
from exponential to 
stationary phase. This 
maximizes MAC yield. 
Apply 10 mL Equilibration 
Buffer to the midiprep column. 
Allow solution to drain by 
gravity flow. 
  
Centrifuge bacterial cells at 
9000 x g for 15 mins. Remove 
supernatant. 
  
Add 8 mL Resuspension Buffer 
w/ RNase A to the pellet and 
resuspend cells until 
homogeneous. 
Do not resuspend 
cells by vortexing. 
Pipette up and down 
instead. 
This avoids the potential of 
shearing the MAC. 
Add 8 mL Lysis Buffer and 
immediately mix by inversion 
until mixture is homogeneous. 
Do not vortex. Incubate at 
room temperature for 5 mins. 
  
Add 8 mL Precipitation Buffer 
and mix immediately by 
inversion until mixture is 
homogeneous. Do not vortex. 
  
Centrifuge lysate at 12,000 x g 
at room temperature for 5 mins. 
  
Load the supernatant onto the 
equilibrated column. Allow the 
solution to flow through by 
gravity. 
  
Wash the column with 2 x 10 
mL Wash Buffer. Discard the 
flow-through. 
  
Place a sterile centrifuge tube 
under the column. 
Make sure this tube is 
a 15 mL tube and not 
a 50 mL tube. 
This allows the MAC to be 
dissolved in a smaller 
amount of water later on. 
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Table 3.2 (continued). 
Add 5 mL Elution Buffer 
warmed to 50°C to elute DNA. 
Discard the column. 
  
Add 3.5 mL isopropanol to the 
elution tube. Mix well. 
  
Centrifuge at 12,000 x g for 30 
mins at 4°C. Carefully remove 
and discard supernatant. 
Incubate tube at room 
temperature for 
additional 30 – 60 
mins before removing 
supernatant. 
This helps increase the 
yields of precipitated MAC. 
Resuspend the DNA pellet in 3 
mL 70% ethanol.  
Make sure the 70% 
ethanol is chilled. 
This improves the removal 
of excess salts from the 
MAC solution. 
Centrifuge at 12,000 x g for 5 
mins at 4°C. Carefully remove 
and discard supernatant. 
  
Air-dry the DNA pellet for 10 
mins. 
  
Resuspend the DNA pellet in 
50 – 100 µL Tris-EDTA (TE) 
buffer. 
Resuspend in warmed 
water instead. Pour 
into a 1.5 mL 
microcentrifuge tube, 
and incubate the 
solution at 50°C for 1 
h. 
- TE can pose problems 
for cloning 
applications, so eluting 
in water is a safer 
choice in that regard. 
- Pouring the MAC 
solution avoids 
potential shearing 
from pipetting. 
- Incubating the solution 
at 50°C helps the 
MAC solubilize; at 
lower temperatures, 
the MAC can form 
aggregates. 
 Centrifuge the elution 
tube at 12,000 x g for 
1 min. 
Pouring the DNA solution 
out of the tube can leave 
liquid along the sides of the 
tube. This increases overall 
yield by collecting the 
leftover liquid that contains 
DNA. 
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These changes to the stock protocol led to greatly improved plasmid yields, on the 
order of 100 µg at a concentration of 1 µg/µL, enough to work with for downstream 
applications like electroporation. 
3.4 MAC Characterization with Sanger Sequencing and Pulsed-Field Gel 
Electrophoresis 
One method employed for characterization of the MAC was Sanger sequencing. 
Samples were sent to Eurofins Genomics for sequencing, using the universal primers 
SV40pA-R, pBABE3, and pEXF. The resulting reads were aligned with the provided 
sequence data for the MAC, as shown in Figure 3.4. Approximately 1,700 base pairs 
were matched with the MAC’s sequence, indicating, in part, that the MAC did have the 
correct sequence. 
 
Figure 3.4. Sanger sequencing results aligned with the MAC. The sequencing reads are highlighted in 
yellow above the provided sequence data, and dark-red regions on the arrows represent regions of the 
sequencing reads that match the plasmid map’s sequence. Image generated by SnapGene software (from 
GSL Biotech; available at snapgene.com). 
 
Typical agarose gels (0.5 – 2.0%) run with a unidirectional electic field cannot 
properly resolve DNA fragments larger than 10 kb, so a CHEF DR-III (Bio-Rad) was 
used to visualize the MAC in its entirety. Pulsed-field gel electrophoresis (PFGE) can 
resolve larger DNA fragments by using electrodes positioned at angles other than 180° 
relative to the gel, as shown in Figure 3.5, and turned on at different intervals instead of 
running continuously. In this way, DNA fragments on the megabase scale can be 
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resolved on an agarose gel (Mawer and Leach, 2013). Digestions were performed with 
SacI, a unique cutter yielding a linear fragment that would allow visualization of the 
MAC in its entirety. The results are shown in Figure 3.6. The midiprep is shown in 
comparison with a positive control sample gifted from Dr. Kouprina. As can be seen, the 
majority of samples were of the same size as the positive control sample, indicating that 
the plasmid prep procedures produced a MAC of the correct size. 
 
 
Figure 3.5. A diagram of PFGE electrophoresis. Image from Mawer and Leach, 2013. 
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Figure 3.6. A PFGE image of purified MAC samples, digested with SacI. From left to right, Lane 1: DNA 
molecular size ladder. Lane 2: positive control (MAC provided by Dr. Kouprina). Lane 3: MAC. 
 
3.5 Summary 
The first major challenge to implementing the MAC as a synthetic biology tool 
was overcome through several adjustments at each step of the transformation and 
purification process. During the process of electroporation into E. coli, cells were shaken 
at low speeds and grown at 30°C; multiple colonies were picked post-electroporation, as 
opposed to single colonies; and entire glycerol stocks were used instead of simple stabs. 
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The purification process also required several changes, like picking the correct kit to use; 
extracting the MAC prior to stationary phase; eliminating vortexing steps; pipetting with 
cut tips; and warming the eluted DNA prior to quantification. These changes yielded 
purified MAC samples that were validated with Sanger sequencing and PFGE 
electrophoresis. 
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CHAPTER FOUR 
 
MOLECULAR CLONING OF TRANSGENES ONTO AN ARTIFICIAL 
CHROMOSOME 
 
In order to actually deliver transgenes to mammalian cells using MACs, they need 
to first be integrated into the MACs themselves. Since conventional molecular cloning 
methods had not been extensively explored in the literature, it remained to be seen 
whether or not such a method could be used to integrate transgenes onto the MAC. This 
chapter covers the work that was done to insert a selectable marker (for nutritional 
selection via glutamine removal) into the MAC via Gibson Assembly and characterize 
the subsequent products. 
4.1 Gibson Assembly as a Cloning Method 
Molecular cloning of transgenes onto the MAC was carried out via Gibson 
Assembly. As seen in Figure 4.1, in Gibson Assembly, the DNA segments to be inserted 
into the target plasmid are generated with polymerase chain reaction (PCR), using 
primers that add overlapping sequences with the target plasmid to the DNA segment. The 
segments generated from PCR are then combined with the linearized target plasmid, 
either through PCR amplification or digestion with restriction enzymes, and three 
additional enzymes: an exonuclease, a polymerase, and a ligase. The exonuclease 
removes single bases from the 5’ end of the DNA segments, creating single-stranded 
overhangs that pair together through base-pair complementarity; the polymerase adds in 
nucleotides to fill in any gaps; the ligase joins the nicked ends of the DNA backbone of 
any segments to create a whole DNA segment (Gibson et al., 2009). 
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Figure 4.1. Diagram of how Gibson Assembly works. Source: www.addgene.org, accessed 2019/10/28. 
 
Gibson Assembly was used to replace the Blasticidin-S resistance cassette with a 
cassette for the glutamine synthetase (GS) gene. As seen in Figure 4.2, the MAC is 
linearized with SacI and BamHI, cutting out the Blasticidin-S resistance cassette, before 
Gibson Assembly is used to insert the GS expression cassette. As mentioned in Chapter 
2, GS is used as a selectable marker in glutamine auxotrophs, like CHOZN GS-/-, and was 
a key transgene to investigate for delivery to mammalian cells. The GS expression 
cassette was derived from pcDNA3.1_Zeo(+)-GS, a gift from Gyun Min Lee, and is 
controlled by an SV40 promoter and poly(A) termination signal. 
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Figure 4.2. A diagram of the process of inserting the GS expression cassette into the MAC. Image credit: 
Dr. Xiaoming Lu (Clemson University). 
 
PCR of the GS expression cassettes was carried out using the reaction setup and 
thermocycling protocol specified by NEB for their Q5 Polymerase. The forward primer 
was designed to anneal to the beginning of the SV40 promoter. Its 5’ overhang contains a 
SacI cut site and 20 bp homologous to the region upstream of the Blasticidin-S resistance 
cassette. The reverse primer was designed to anneal to the end of the SV40 poly(A) 
signal. Its 5’ overhang contains a BamHI cut site and 20 bp homologous to the region 
downstream of the Blasticidin-S resistance cassette. 
For Gibson Assembly, 251 ng of the MAC was combined with 131.3 ng of the GS 
insert obtained from PCR, for a 1:8 vector:insert molar ratio, along with Gibson 
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Assembly Master Mix. The mixture was incubated and electroporated according to 
NEB’s associated protocols for Gibson Assembly. 
4.2 Gibson Assembly of GS Expression Cassette into MAC 
Figure 4.3 shows an agarose gel of the PCR products from pcDNA3.1_Zeo(+)-
GS. Of note, two bands showed up in the gel. The Bleomycin resistance cassette (BleoR) 
is also controlled by an SV40 promoter and poly(A) termination signal, as shown in 
Figure 4.4. From the plasmid’s sequence data, the GS cassette was expected to be 1.6 kb, 
and the BleoR cassette was expected to be 1.1 kb, and the bands on the gel match these 
expected values. 
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Figure 4.3. Agarose gel of PCR products from pcDNA3.1_Zeo(+)-GS. From left to right, Lane 1: 1 kb 
DNA molecular size ladder. Lane 2: No template control (NTC), a negative control. Lane 3: PCR products 
from pcDNA3.1_Zeo(+)-GS, abbreviated GS. Both products, corresponding to GS and BleoR, are pointed 
out. 
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Figure 4.4. Plasmid map of pcDNA3.1_Zeo(+)-GS. Image generated by SnapGene software (from GSL 
Biotech; available at snapgene.com). 
 
The band containing the GS expression cassette was cut out and recovered with a 
Monarch DNA Gel Extraction Kit (NEB). A subsequent agarose gel, Figure 4.5, showed 
a single clean band corresponding to the size of the GS expression cassette. The MAC 
double-digested with SacI and BamHI is also shown, to demonstrate that both pieces 
necessary for Gibson Assembly were present. 
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Figure 4.5. Agarose gel containing the purified insert and vector fragments for Gibson Assembly. From left 
to right, Lane 1: DNA molecular size ladder. Lane 2: GS cassette produced from PCR. Lane 3: linearized 
MAC. 
 
Post-Gibson Assembly, the products were electroporated into E. coli DH10β, 
plated, and incubated at 30°C. As can be seen in Figure 3.12, one colony, labeled “MAC-
GS,” popped up on a plate, seen in Figure 4.6. A midiprep of this colony yielded ~100 µg 
at a concentration of ~1100 ng/µL. 
In terms of increasing cloning efficiency, the best place to start would involve 
increasing the amount of vector DNA used. Since the MAC is much larger than typical 
plasmid vectors, mass units can be misleading, since the molecular weights of the MAC 
and typical plasmid vectors are so different. A given mass amount of the MAC represents 
a smaller molar amount than the same mass of a typical plasmid vector would. For 
example, for the modified Gibson Assembly protocol, 500 ng of the MAC is equivalent 
to 0.0135 pmol. In contrast, 500 ng of pUC19, a commonly-used cloning vector, is 
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equivalent to 0.302 pmol, a ~22-fold increase in molar amount. For a 1:8 vector:insert 
ratio, with that low a molar amount of the MAC, it ends up being the limiting reagent in 
the Gibson Assembly process. Using a higher vector mass could lead to higher colony 
counts from subsequent transformation into E. coli. 
 
  
Figure 4.6. Agar plate of E. coli DH10β transformed with the MAC-GS Gibson Assembly product. 
 
4.3 Verification of Gibson Assembly Success 
To verify the presence of the GS cassette on the MAC, two different PCR 
verification steps were used. In one PCR, the primers used for Gibson assembly were 
used, and MAC-GS was compared to a no-template control (N.C.), a positive control 
(P.C.), pcDNA3.1_Zeo(+)-GS, and the original MAC, as seen in Figure 4.7. The positive 
control yielded 2 bands, as expected; the no-template control yielded nothing, as 
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expected, the MAC yielded a band of 1.8 kb, the size of the blasticidin cassette, and GS-
MAC yielded a band that matched the larger band on the positive control lane. 
 
 
Figure 4.7. PCR verification of Gibson Assembly, using Gibson Assembly primers. From left to right, Lane 
1: 1 kb DNA molecular size ladder. Lane 2: Positive control (P.C), pcDNA3.1_Zeo(+)-GS. Lane 3: 
Negative control (N.C), PCR without DNA template. Lane 4: MAC. Lanes 5 and 6: the Gibson Assembly 
(GA) product, MAC-GS. 
 
As further verification of the success of Gibson Assembly, another PCR was 
performed on MAC-GS with a different set of verification primers. The forward primer 
had homology with the MAC, while the reverse primer had homology with the GS 
expression cassette, as seen in Figure 4.8. A band of 1.9 kb was expected from the PCR 
reaction; Figure 4.9 shows an agarose gel of the PCR results, confirming the expected 
size and the presence of the GS cassette on the MAC. 
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Figure 4.8. The location of the verification primers on MAC-GS. Image credit: Dr. Xiaoming Lu (Clemson 
University). 
 
                         
Figure 4.9. Agarose gel of PCR with verification primers. From left to right, Lane 1: Negative control 
(N.C.), PCR without DNA template. Lane 2: 1 kb DNA molecular size ladder. Lane 3: MAC-GS, with the 
band’s size labeled. 
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To ensure that MAC-GS was the correct size and had not lost repeats somewhere 
along the way, PFGE was also performed on MAC-GS, as seen in Figure 4.10. MAC-GS 
and the original MAC were double-digested with BamHI and SacI, as well as single-
digested with EcoRV, which cuts uniquely. The digests of MAC-GS and the original 
MAC are very close in size, and, combined with the EcoRV digests, show that MAC-GS 
did not lose repeats. 
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Figure 4.10. PFGE analysis of MAC-GS. (a) PFGE analysis with restriction enzymes BamHI and SacI. 
From left to right, Lane 1: DNA molecular size ladder (M). Lane 2: The original MAC, as a positive 
control for size. Lane 3: MAC-GS. (b) PFGE analysis with restriction enzyme EcoRV. Lane 1: DNA 
molecular size ladder (M). Lane 2: The original MAC. Lane 3: MAC-GS. 
 
Samples were also sent off to GeneWIZ for Sanger sequencing. The resulting 
sequence data was aligned to the GS expression cassette; about 900 base pairs were 
successfully matched, showing that the Gibson assembly product did indeed contain part 
of the GS expression cassette.  
(a) (b) 
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Figure 4.11. Sequencing reads aligned to the GS expression cassette. The sequencing reads are highlighted 
in yellow above the provided sequence data, and dark-red regions on the arrows represent regions of the 
sequencing reads that match the plasmid map’s sequence. Image generated by SnapGene software (from 
GSL Biotech; available at snapgene.com). 
  
4.4 Summary 
The challenge of cloning transgenes onto a MAC via conventional cloning 
methods was met. Via Gibson Assembly, an expression cassette for the GS gene was 
cloned onto the MAC, and the subsequent products were confirmed to be consistent with 
correct assembly via restriction digest and PFGE, PCR, and Sanger sequencing. 
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CHAPTER FIVE 
 
DELIVERY OF TRANSGENES ON AN ARTIFICIAL CHROMOSOME TO 
MAMMALIAN CELLS 
 
Once a transgene had been successfully integrated onto the MAC, the other 
important objective to achieve was actually delivering these constructs to mammalian 
cells. As work in the literature by previous groups did not extensively cover delivery of 
the MAC to suspension CHO cells, finding a suitable method was necessary. 
Electroporation was the standard method for delivering DNA constructs to suspension 
CHO cells; that served as the starting point for studies of MAC delivery. This chapter 
describes the work conducted to characterize a positive control construct for MAC-GS, 
NBS1-GFP; deliver NBS1-GFP and MAC-GS to CHOZN GS-/- cells via electroporation; 
assess electroporation success and efficiency; and determine transgene functionality via 
L-glutamine selection. 
5.1 Verification of Positive Control Constructs NBS1-GFP and VHL-GFP 
Finding an appropriate positive control for delivery studies on a MAC is difficult, 
due to its size. Few readily available DNA constructs approximate the expected size of 60 
kb for a MAC. Dr. Jung Hyun Kim was kind enough to donate a pair of constructs to 
serve as positive controls, NBS1-GFP (~76 kb in size) and VHL-GFP (~46 kb). These 
constructs had been used in a previously-published paper along with MACs to correct 
genetic deficiencies in human cells (Kim et al., 2011); a sequence map of VHL-GFP is 
shown in Figure 5.1. These constructs had the desired qualities for a useful positive 
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control (namely, a size approximate to that of a MAC and a reporter gene that produces 
an FP). 
 
 
Figure 5.1. A plasmid map of VHL-GFP. Image from Kim et al., 2011, reproduced with permission. 
 
Post-maxiprep, PFGE was performed to visualize restriction digests of NBS1-
GFP and VHL-GFP, as seen in Figure 5.2. Both constructs were digested with NotI-HF 
and run against undigested versions. The digested version of VHL-GFP produced 3 
fragments, analogous to the 3 NotI cut sites displayed in Figure 5.1. The three fragments 
on the gel correspond roughly to the three fragments predicted by the plasmid map: 33.3 
kb, 7.8 kb, and 5.5 kb. The latter two fragments are difficult to predict because the ladder 
loaded only goes as low as 15 kb, but the 33.3 kb fragment appears to match up with the 
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predicted value. While an NBS1-GFP plasmid map was not available from the cited 
article, it was constructed in the same manner as VHL-GFP. NBS1 is about 30 kb larger 
than VHL, and the larger fragment seen in the lane for NBS1-GFP appears to be about 30 
kb larger than the largest fragment seen in the lane for VHL-GFP. From this, it can be 
inferred that the purified NBS1-GFP and VHL-GFP constructs were, indeed, the right 
size. 
 
 
Figure 5.2. PFGE image of VHL-GFP and NBS1-GFP. Lane 1: VHL-GFP. Lane 2: NBS1-GFP. Lane 3: 
DNA molecular size ladder. 
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To demonstrate the functionality of NBS1-GFP and VHL-GFP, Dr. Jung Hyun 
Kim transfected both constructs into HT1080 fibrosarcoma cells with X-tremeGENE 9 
(Roche), a cationic lipid reagent similar to Lipofectamine 2000/3000 (Invitrogen). 
HT1080 cells were seeded into a 6-well plate 24 h prior to transfection such that the cells 
would be 70% confluent at the time of transfection. Transfection was carried out 
according to manufacturer’s instructions. Cells were imaged 24 h post-transfection and 
can be seen in Figure 5.3. 
 
          
Figure 5.3. Fluorescence images of HT1080 fibrosarcoma cells transfected with X-tremeGENE9 (Roche). 
Fluorescent cells are pointed out with white arrows. (a) VHL-GFP. (b) NBS1-GFP. Image credit: Dr. Jung 
Hyun Kim (National Institutes of Health). 
 
5.2 Electroporation of NBS1-GFP into CHOZN GS-/- 
Once the size and functionality of NBS1-GFP and VHL-GFP had been verified, 
they were used as positive controls for electroporation. Since both constructs had the 
same functionality and only really differed in size, NBS1-GFP was used, on the basis 
that, if success was found with a 76 kb construct, success could be found with a smaller 
60 kb MAC containing transgenes. 
(a) (b) 
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The protocol used for electroporation was provided in the CHOZN® Platform 
Technical Bulletin. In short, for each electroporation, 6.25 x 106 cells were isolated from 
a culture seeded 24 h beforehand, and 5 x 106 cells were combined with 30 – 50 µg of 
DNA. The cell-DNA mix was loaded into a 4 mm gap electroporation cuvette and 
electroporated with a Gene Pulser Xcell machine (Bio-Rad) using an exponential decay 
pulse at 300 V and 950 µF. The cells were transferred to 5 mL of growth medium in a 
suspension T25 flask (Greiner Bio-One) and observed 24 h later. For electroporation of 
NBS1-GFP, higher masses were used; the quoted range in the electroporation protocol 
was presumed to apply to smaller, high-copy plasmids, and an equivalent mass of a 
larger, low-copy plasmid would contain a lesser molar amount. 
~100 µg NBS1-GFP was electroporated into CHOZN GS-/- cells, and the cells 
were observed under fluorescence 24 h post-electroporation, as seen in Figure 5.4. To 
estimate efficiency, 100 µL of culture was diluted into 1 mL total of growth medium in a 
well of a 24-well plate, and 5 fields of view were imaged; one such image is shown in 
Figure 5.4. Of 914 counted cells, 18 fluoresced, yielding an electroporation efficiency of 
1.97%. This number may seem low, but it makes sense when taking into account the 
relationship between the size of a DNA construct and the efficiency of electroporating it 
into cells. The scale of electroporation is also important to consider: 1.97% of 5 x 106 
cells is 98,500 cells, which is not an insignificant amount and not prohibitive for the 
purposes of selection. 
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Figure 5.4. Fluorescence overlay image of CHOZN GS-/- cells electroporated with NBS1-GFP. Cells 
diluted 1:10 in growth medium prior to capturing images. Image taken at 10x objective. 
 
To further verify the efficiency estimates, this experiment was independently 
conducted by Baylee Westbury, an undergraduate member of the project team. Cells were 
diluted and plated as before, except that the cells were diluted in a 1:20 ratio for ease of 
counting. One such image is shown in Figure 5.5. Of 290 cells counted, 6 cells 
fluoresced, yielding an efficiency of 2.07%. 
 
 
Figure 5.5. Fluorescence overlay image of CHOZN GS-/- cells independently electroporated with NBS1-
GFP. Cells diluted 1:20 in growth medium prior to capturing images. Image taken at 10x objective. 
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As a more quantitative method of evaluating efficiency, flow cytometry was 
carried out on CHOZN GS-/- cells electroporated with NBS1-GFP. 18 h post-
electroporation, cells were analyzed with an NL-2000 flow cytometer (Cytek) with a 488 
nm laser. The events corresponding to the general cell population were subsequently 
gated off. The bulk of the events observed had a mean fluorescence intensity (MFI) of 
less than 104; these events were taken to represent autofluorescence of the cells that did 
not take up NBS1-GFP. Any event exhibiting a higher MFI than 104 was gated off 
separately to represent the cells that had taken up NBS1-GFP. Figure 5.6 shows 
histograms of the fluorescence intensities of the general cell population (at left) and the 
population exhibiting high fluorescence intensities (at right). Of the 4,567 events 
observed in the general cell population, 101 showed a fluorescence intensity higher than 
104, indicating an electroporation efficiency of 2.21%, a value similar to the percentages 
obtained from manual cell counting. 
  
 55
               
Figure 5.6. Flow cytometry data of CHOZN GS-/- cells electroporated with NBS1-GFP. The y-axis is 
counts of flow cytometry events, and the x-axis is the mean fluorescence intensity of B3, the most sensitive 
blue laser detector channel on the NL-2000, on a biexponential scale. (a) The general cell population, with 
the P1 gate showing the biggest cluster of the general cell population. (b) The fluorescence signal of the 
cells gated by P1. Fluorescence intensity from the strongest laser channel is displayed on the x-axis. 
 
5.3 Electroporation of CHOZN GS-/- Cells with MAC-GS  
Now that an efficiency had been established for electroporation of large 
constructs into CHOZN GS-/-, electroporating MAC-GS into CHOZN GS-/- was the next 
step. 39 µg MAC-GS was electroporated into CHOZN GS-/-, as detailed in Section 5.2, 
and, 24 h post-electroporation, cells were scaled up from 5 mL of growth medium in a 
T25 suspension flask to 10 mL of growth medium without L-glutamine in a T75 
suspension flask (Greiner Bio-One). Cells were counted at least twice weekly, and the 
medium was changed once a week, according to the CHOZN® Platform Technical 
Bulletin, until viabilities passed 90%. As seen in Figure 5.7, the cells took approximately 
19 days to recover from selection; viable cell density at the end of selection was 6.8 x 106 
cells/mL. 
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Figure 5.7. MAC-GS viability and viable cell density under selection by removal of L-glutamine. 
 
5.4 Summary 
The challenge of delivering MACs loaded with a transgene to suspension CHO 
cells was met. Positive control constructs for the MAC, NBS1-GFP and VHL-GFP, were 
obtained, and their size and function were verified through PFGE and cationic lipid 
transfection into HT1080 fibrosarcoma cells. Electroporation of NBS1-GFP into CHOZN 
GS-/- produced a low number of successfully electroporated cells but enough cells to 
proceed with selection. Efficiencies were estimated from epifluorescence microscopy and 
flow cytometry. MAC-GS was subsequently electroporated into CHOZN GS-/-, and 
selection by removal of L-glutamine yielded a culture of viable cells. 
  
 57
CHAPTER SIX 
 
SUMMARY OF EXPERIMENTAL RESULTS AND FUTURE DIRECTIONS 
 
6.1 Summary of Experimental Results 
Chapter 3 addresses the first technical challenge of purifying the MAC in high 
yield and characterizing it. The MAC sample gifted by Dr. Kouprina was electroporated 
into E. coli DH10β, and positive colonies were recovered from the subsequent agar 
plating. A PureLink® HiPure Plasmid Midiprep Kit was used to extract the MAC from E. 
coli culture, producing yields of up to 100 µg. For verifying the characteristics of the 
MAC recovered via plasmid prep, Sanger sequencing confirmed the sequence data of 
some regions of interest on the MAC for subsequent cloning, and PFGE confirmed the 
MAC’s size as equivalent to that of a positive control sample MAC. 
Chapter 4 addresses the next technical challenge of cloning transgenes onto the 
MAC. Gibson Assembly was used to replace the Blasticidin-S resistance expression 
cassette with a cassette for expression of glutamine synthetase, and a colony was 
recovered from subsequent electroporation into E. coli DH10β. To verify the 
characteristics of the assembly product MAC-GS, PCR was used to demonstrate the 
presence of the GS expression cassette; PFGE was used to confirm the size of MAC-GS; 
and Sanger sequencing was used to confirm the sequence of the GS expression cassette 
itself. 
Chapter 5 addresses the last technical challenge of delivering the MAC with a 
transgene to mammalian cells and efforts to do so with electroporation. Electroporation 
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was carried out with different positive control constructs, NBS1-GFP and VHL-GFP; 
these constructs were initially run on a PFGE gel to confirm construct size and 
transfected into HT1080 fibrosarcoma cells for functional verification. Electroporation of 
NBS1-GFP into CHOZN GS-/- yielded low efficiencies but a not-insignificant number of 
transfected cells, a result validated by epifluorescence microscopy and flow cytometry. 
Electroporation of MAC-GS and subsequent nutritional selection yielded a viable culture 
of CHOZN GS-/- cells. 
6.2 Future Directions 
 This project has shown some potential success in terms of cloning transgenes onto 
artificial chromosomes and delivering them to mammalian cells. However, much work 
remains to be done in this area, and many questions still remain unanswered: 
1) Does a MAC remain as a separate chromosome or integrate into the genome? One 
way to do this is to carry out whole genome sequencing and align the results to 
the CHO reference genome. If a MAC has remained a separate construct, the 
sequencing reads corresponding to a MAC should align very poorly to the 
reference genome, as there is little homology between a MAC and the CHO 
genome. If a MAC has integrated, then there should be some reads containing 
partial homology to the reference genome. 
2) Can a MAC remain as a separate chromosome over 60 generations, a typical 
duration for assessing clonal stability in CHO cells? One way to do this is by 
tracking the copy number of the GS gene, via quantitative PCR (qPCR), in the 
MAC-GS CHO strain in the presence or absence of selection pressure, with 
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CHOZN GS-/- and CHO K1 (which has an intact GS gene) as benchmarks to 
compare GS gene expression to. 
3) Can multiple transgenes (e.g. expression cassettes for IgG light and heavy chains) 
be inserted into a MAC? This would require further Gibson Assembly 
experiments. Measuring IgG titer would be the way to determine whether or not 
CHO cells with a MAC containing transgenes for IgG production can match the 
titer of a CHO cell strain with integrated transgenes for IgG production. 
That being said, the foundation of viability for cloning a transgene onto a MAC 
and delivering it to mammalian cells (two tasks that were non-trivial and required much 
time and effort) has been laid down, paving the way for subsequent inquests into 
executing MACs as a usable technology in bioengineering. 
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Appendix A 
Histone-Mediated Transfection as a Delivery Method 
  
Histone-mediated transfection was of interest as a delivery method and a possible 
augmentation of electroporation. This appendix describes the work done to express and 
purify histones in E. coli; characterize the histones  
A.1 Expression of Histones in E. coli 
 One particular downside to producing histones for use in HMT comes during the 
purification process. The fusion proteins produced in the study by Wagstaff et al. were 
purified under denaturing conditions, which adds additional steps and time for 
purification. Shim et al. (2012) improved the process of histone production by performing 
purification at high salt concentrations (2.0 M sodium chloride), using a polycistronic 
vector that would produce all four core histones at once, pET29a-YS14 (a gift from Jung-
Hyun Min). At these conditions, histones dissociate from DNA and can remain in 
solution instead of dropping out into inclusion bodies. This simplified the process of 
histone purification, due to the non-denaturing conditions used. Non-denaturing 
conditions would greatly simplify the purification procedure, as opposed to having to 
denature proteins, isolate the resulting inclusion bodies, and then re-fold the proteins. 
The vector pET29a-YS14 was purified from an E. coli DH5α stock with a 
PureYield Maxiprep Kit (Promega) and then transformed into E. coli BL21(DE3). A 
colony from the transformation was inoculated into 10 mL 2x YT medium and shaken at 
170 rpm for 4 h at 37 °C. That culture was then seeded into 1 L of the same medium and 
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grown at the same conditions until the OD reached ~0.4. A sample of culture was taken at 
this point for further verification of expression. IPTG was added to the culture, to a final 
concentration of 0.4 mM, to induce expression. The culture was shaken for another 20 h. 
Cells were pelleted at 4,500 x g for 10 mins at 4 °C and stored at -20 °C for future 
purification. 
The cell pellet was re-suspended in 60 mL lysis buffer (20 mM Tris-Cl, pH 8.0; 2 
M sodium chloride; 1 mM phenylmethanesulfonylfluoride (PMSF); 0.5 mM tris(2-
carboxyethyl)phosphine (TCEP)). Lysis was carried out via sonication, using a 
Fisherbrand Model 120 Sonic Dismembrator (Fisher Scientific). The cell pellet was 
sonicated for 6 mins, at 70% power, on a 5 s off, 5 s on cycle. A sample of the cell lysate 
was saved for verification of expression. 
 
 63
 
Figure A.1. SDS-PAGE of un-induced and induced E. coli cultures. From left to right, Lane 1: 
molecular weight ladder. Lane 2: E. coli culture not induced with IPTG. Lane 3: E. coli culture induced 
with IPTG. The bands corresponding to induced histones are indicated. 
 
Verification of expression was performed by running cell lysate samples on an 
18% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel, to 
separate the various proteins in the samples. Un-induced and induced E. coli samples 
were run on the gel to determine whether the histones had been expressed. The gel was 
subsequently stained with Coomassie Blue, which binds to proteins, and de-stained. 
Imaging of the gel, as well as all subsequent SDS-PAGE gels, was performed on a LI-
COR Odyssey CLx. As seen in Figure A.1, bands that corresponded to the molecular 
weights of the histones and did not appear to show up in the un-induced culture were 
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pointed out on the gel. Size estimates were based on calculations of the expected weights 
from the vector’s sequence data. Histone H2A was expected to be ~17.9 kDa because of 
the associated S-tag, 6x His tag, and thrombin cleavage site. Histone H4 was expected to 
be ~13.2 kDa due to the additional associated thrombin cleavage site and 6x His tag. This 
gel showed at least preliminary evidence that the cells had properly expressed the 
histones. 
A.2 Purification of Histones with Fast Protein Liquid Chromatography (FPLC) 
The cell lysate was spun at 38,500 x g for 1 h at 4 °C in order to clarify the lysate. 
Such high speeds were necessary to remove the majority of the larger proteins, as the 
histones were smaller than 20 kDa. After centrifugation, the supernatant was collected 
and filtered through a 0.45 µm filter to remove particulates that might interfere with 
subsequent purification. Stock imidazole solution was added to a final concentration of 
30 mM for subsequent chromatography. 
The lysate was loaded onto a 5 mL HisTrap HP column (GE Healthcare) with an 
NGC Chromatography System (Bio-Rad) that had been equilibrated with Ni-buffer A (20 
mM Tris-Cl, pH 8.0; 2 M sodium chloride; 0.5 mM TCEP). Two washes were performed: 
10 CV of Ni-buffer A with 30 mM imidazole, and 10 CV of Ni-buffer A. Elution was 
performed using a step gradient of imidazole in Ni-buffer A: 60 mM, 110 mM, 140 mM, 
170 mM, and 500 mM. The choices of 110 mM, 140 mM, and 170 mM were based on 
Shim et al., which had reported 110 mM and 170 mM as the ranges in which they saw 
roughly stoichiometric ratios of histones. The resulting chromatogram and a portion of it 
zoomed in on the elution steps are shown in Figures A.2 and A.3. 
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Figure A.2. FPLC chromatogram. Absorbance at 280 nm is shown as the orange trace. Relevant fractions 
that were run on SDS-PAGE are indicated. 
 
 
Figure A.3. FPLC chromatogram, zoomed in to elution step gradient. Relevant fractions that were run on 
SDS-PAGE are indicated. 
 
The fractions pointed out in the chromatograms and the lysate pre-purification 
were run on a 4 – 20% gradient SDS-PAGE to observe the size of the eluted proteins, as 
seen in Figure A.4. The input and flow-through were run in order to show that the column 
did actually pick up the proteins of interest. The wash fraction was shown in order to 
demonstrate that the undesired proteins were being washed out. Each of the fractions 
from the elution corresponded to a potential peak seen on the A280 trace (in orange). 
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Figure A.4. SDS-PAGE of FPLC fractions post-purification. 
 
The difference from the input appears to show bands in the 15 kDa range that are 
stronger in the input than the flow-through fraction. The bands from the various elution 
peaks show weak bands of other proteins at higher molecular weights, but the band from 
peak 5 shows the presence of two strong bands in the ranges of the expected values for 
histone sizes. It was slightly odd that the proteins eluted at such a high concentration of 
imidazole and not beforehand. However, this can potentially be explained by the fact that, 
while the stock Tris-Cl buffer was adjusted to pH 8.0 at room temperature, the FPLC was 
operated at 4 °C. The pH of Tris base is influenced by temperature; for instance, a 50 mM 
solution of Tris base that has a pH of 8.0 at 25 °C will, at 5 °C, have a pH of 8.58. This 
changes the ability of Tris base to act as a buffer and maintain the solution’s overall pH, 
which can subsequently impact the binding interactions involved in affinity 
chromatography. 
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A.3 Identification of Histones using Peptide Mass Fingerprinting 
It was fairly likely that the band from peak 5 showed the presence of the histones 
in question, but, to confirm protein identity, a sample of the fraction was sent off to a 
collaborator, Alex von Kriegsheim, for identification via peptide mass fingerprinting. The 
unknown protein was cleaved into smaller peptide fragments using a protease. The 
peptides were then analyzed with mass spectrometry, and the resulting masses were run 
against a protein database to match them to expected peptide masses from known 
proteins. Known proteins that matched were returned as accession numbers. The 
accession numbers were then searched on UniProt to obtain the names of the proteins, 
and the four core histones were identified, as shown in Table A.1. 
 
Table A.1. Accession numbers from mass spectrometry and their corresponding identities 
from UniProt. 
Accession Number Identity 
A0A1L8G0S8 X. laevis histone H4 
A0A1L8G0S1 X. laevis histone H3 
Q92130 X. laevis histone H2B 
Q6INC9 X. laevis histone H2A 
 
A.4 Ultrafiltration of Histones and Quantification of Histone Concentration 
In order to quantify the concentration of histones in the fraction, the Pierce Rapid 
Gold BCA Assay Kit (Thermo Fisher) was used. However, the kit is incompatible with 
high concentrations of imidazole and TCEP, so a portion of the histones was first buffer-
exchanged to phosphate-buffered saline (PBS) via ultrafiltration, using an Amicon 10K 
molecular weight cutoff (MWCO) filter. 500 µL of the histones was spun at 14,000 x g 
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for 20 minutes, after which the volume of the retentate was measured before being 
brought back up to 500 µL with PBS. This process was repeated 3 times. In this way, the 
calculated concentrations of imidazole and TCEP were sufficiently diluted as to not 
impact the BCA assay’s results, as well as to avoid cytotoxicity in future cell culture 
experiments. 
A potential concern was raised with regards to the size of the proteins. The 
histones themselves are around 15 kDa in size, so a 10K MWCO could potentially let 
proteins through. However, from Shim et al., the histones appeared to associate in 
solution to form nucleosomes, complexes of ~111 kDa, meaning that a 10K MWCO  
should be sufficient for buffer exchange. To test this, the filtrates and retentates after each  
of the spins were run on an SDS-PAGE to see if proteins were leaking through the filters. 
As can be seen in Figure A.5, it does not appear as though the 10K MWCO filter allowed 
any protein to leak through (or it did so in undetectable amounts). 
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Figure A.5. SDS-PAGE of permeates and retentates from ultrafiltration. From left to right, Lane 1: protein 
molecular weight ladder. Lane 2: the histones before carrying out buffer exchange. Lane 3: the permeate 
from the filter after 1 spin. Lane 4: the permeate from the filter after 2 spins. Lane 5: the permeate from the 
filter after 3 spins. Lane 6: the histones in the retentate after 3 spins. 
 
A bicinchoninic acid (BCA) assay was subsequently run in order to quantify 
protein concentration. Protein standards of bovine serum albumin (BSA) in PBS were 
made, from 50 to 2000 µg/mL, in order to construct a standard curve, shown in Figure 
A.6, to judge the histone samples against. A linear regression of concentration vs. 
absorbance, in accordance with Beer’s Law, shows a linear trend with a correlation 
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coefficient of 0.9987. Using the standard curve, the histone sample was estimated to be 
371.6 ng/µL. 
 
 
Figure A.6. Standard curve from BCA assay. 
 
A.5 Experimental Approach to Histone-Mediated Transfection 
In order to test the efficacy of histone-mediated transfection (HMT) in cell 
culture, pilot studies were first conducted with HEK 293, a commonly-used cell line that 
grows quickly, is easy to work with, and had been successfully transfected with reporter 
genes in the past. The DNA payload of choice for initial tests was mTFP1-C1, a gift from 
Robert Campbell and Michael Davidson (Ai et al., 2008). mTFP1-C1 is a 4.7 kb vector 
that expresses the FP mTFP1. FP genes were the reporter genes of choice for gene 
delivery experiments because of the quick turnaround in observing results. Nutritional or 
antibiotic selection can take anywhere from 1 to 3 weeks; in contrast, FPs can be seen 
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inside of cells via fluorescence microscopy within 24 h, a much shorter time period 
necessary for evaluation of gene delivery success and efficiency. 
Initial DNA:cell and histone:DNA ratios were derived from Wagstaff et al. 
Originally, a 15x15 mm coverslip seeded to 80 – 90% confluency was transfected with 
10 µg DNA. Scaling down to the growth area of a 96-well plate (0.32 cm2) yielded 1.42 
µg DNA. As for the histone:DNA ratio, a simplified calculation of 1 histone per 208 bp 
DNA was used. This calculation did not assume that the DNA would definitively wrap 
around the histone, but it served as a simplifying assumption. Using this conversion, 1.42 
µg mTFP1-C1 required 168.5 ng histones. 
 Wells of a 96-well plate were seeded at 10,000 cells/well and transfected 48 h 
later. A 2-fold change in either direction for both mTFP1-C1 and the histones were 
included. The negative control was set as histones with no DNA payload. For the positive 
control, lipofectamine, as an established transfection reagent, was used to transfect 
mTFP1-C1. Histones were mixed with mTFP1-C1 and brought up to 50 µL total volume 
with growth medium before being incubated at room temperature for 15 mins. The 
histone-DNA mix was incubated with cells for 1 h at 37 °C before adding 50 µL DMEM. 
Cells were incubated for 48 h post-transfection and observed with a Revolve microscope 
(Echo), using a 488 nm laser. 
A.6 Histone-Mediated Transfection in HEK 293 
Results of initial HMT experiments can be seen in Figure A.7. As expected, the 
negative control showed no fluorescence. The positive control showed many cells 
fluorescing, as expected. Looking at the well with the specified DNA and histone masses 
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(1.42 µg and 168.5 ng, respectively), only a few cells in the field of view showed 
fluorescence. The transillumination view is shown, as well, to demonstrate the number of 
cells in the field of view. Modifying the DNA mass while keeping histone mass constant 
did little to increase the number of transfected cells; however, increasing the number of 
histones without changing DNA mass led to a marked increase in the number of cells 
transfected. This result showed promise in terms of HMT, especially the trend of 
increasing the histone:DNA ratio, with the caveat of the cells essentially forming a 
monolayer. This was due to the original protocol’s stipulation that transfection occur at 
80 – 90% confluency and then waiting 48 h post-transfection to observe efficiency. 
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(a) 
 
(b) 
 
Figure A.7. Initial histone-mediated transfection experiments. (a) Fluorescence image of HEK 293 cells 
transfected with 1.42 µg mTFP1-C1 and 166.5 ng histones. (b) Fluorescence image of HEK 293 cells 
transfected with 1.42 µg mTFP1-C1 and 333 ng histones. 
 
The next question to explore, then, was how increasing histone mass even further 
would affect the number of cells transfected. Histone mass was increased by up to 16-
fold (for a final mass of 2.66 µg histone), for the same DNA ranges tested in the previous 
experiment. While there was not a clear trend to be seen in the results, the trials with 
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higher histone masses (1.33 µg and 2.66 µg shown below) did show a marked increase in 
the number of fluorescent cells compared to the trials with lower histone masses (666 ng  
shown in Figure A.8). A possible explanation for this is that circular DNA merely 
associates with histones through electrostatic interactions to facilitate HMT instead of 
actually wrapping around the histones. 
 
  
 
 
 
 
Figure A.8. HMT experiments with increased histone:DNA ratios. DNA mass for this set of images was 
maintained at 1.42 µg. (a) Transfection with 666 ng histones. (b) Transfection with 1.33 µg histones. (c) 
Transfection with 2.66 µg histones. 
 
(a) (b) 
(c) 
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A.7 Electroporation and Histone-Mediated Transfection in CHOZN GS-/- 
A.7.1 Initial Combinations of Electroporation and HMT 
At this point, having established the ability of HMT to transfect mammalian cells, 
period, attention was turned to transfecting the CHOZN GS-/- suspension cell line. To 
reiterate, electroporation was the standard method of gene delivery for CHOZN GS-/-; 
Sigma already had an electroporation protocol in place for it. HMT was of interest in the 
hopes that it would have an additive effect on efficiency when combined with 
electroporation. Some combinations of electroporation and histone-mediated transfection 
were explored: HMT alone, HMT followed up by electroporation of cells (HMT/E), and 
electroporation followed immediately by HMT (E/HMT). The workflows for each of 
these avenues are shown in Figure A.9. 
 
Figure A.9. Experimental steps for each of the combinations of HMT and electroporation. Image credit: Dr. 
Xiaoming Lu (Clemson University). 
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The plasmid construct ColorfulCell was utilized as a positive control. 
ColorfulCell, a gift from Pierre Neveu (Sladitschek and Neveu, 2015), is a 14.7 kb 
construct that contains 6 unique FPs (Citrine, 3 copies of mCerulean, 3 copies of 
TagBFP, hmAzami-Green, iRFP670, and mCherry) and was considered a useful reporter 
gene construct due to its larger size than that of mTFP1-C1. 
6.5 µg ColorfulCell were used in these experiments, due to limitations on the 
amount of MAC that could be extracted from E. coli cultures at the time that have since 
been remedied. On the basis of the previously-mentioned simplifying assumption of 1 
histone per 208 bp DNA, 6.1 µg histones were used for these experiments. 
Electroporation was carried out with a modified version of Sigma’s standard 
protocol for electroporating CHOZN GS-/- cells. Cells from a CHOZN GS-/- culture were 
initially counted to determine viability; electroporation requires culture viability of above 
90%. Once viability was determined, for each sample to be electroporated, 6.25 x 106 
cells were isolated from the culture, centrifuged at 220 rcf for 5 mins, and re-suspended 
in 1 mL CD CHO Fusion medium (SAFC), supplemented with 5 mM L-glutamine. The 
DNA – histone mix was added to 800 µL cells, and 600 µL of that mixture was added to 
a 4 mm gap cuvette (VWR). The cuvette was electroporated with an exponential decay 
pulse at a capacitance of 950 µF. The standard voltage specified by Sigma was 300 V, 
but it had been optimized to 270 V, based on a protocol from another article (Panousis et 
al., 2005), for lower amounts of mTFP1 and ColorfulCell, on the basis of efficiency and 
cell viability post-electroporation. Post-electroporation, cells were incubated at room 
temperature for 5 mins to allow cell membranes to re-seal and then transferred to a T25 
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suspension flask (Greiner Bio-One) with 5 mL CD CHO Fusion medium, supplemented 
with 5 mM L-glutamine. 
Cells were imaged on the Echo Revolve 24 h post-transfection. Samples were 
diluted 1:10 in growth medium for ease of cell counting, and 5 fields of view were 
captured on the Echo Revolve for calculating efficiency. Efficiencies were calculated 
from the average of counts from all 5 fields of view. 
Figures A.10(a) and A.10(b) show HMT/E and its positive control (ColorfulCell 
only, without histones); roughly the same efficiency was estimated for each (6.6% for the 
sample vs. 4.5% for the positive control). Figures A.10(c) and A.10(d) show E/HMT and 
its positive control (ColorfulCell only, without histones); almost no cells lit up for either 
of the sample and the positive control (<0.25% efficiency for each). HMT alone (Figure 
A.10(e)) yielded no observable fluorescent cells. From these results, it appeared that 
following electroporation up with HMT had no real effect whatsoever. HMT itself 
appeared to have no discernible effect on electroporation as a gene delivery method. 
HMT alone appeared to have zero effect on cells in suspension culture. 
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Figure A.10. Representative fluorescence images of combinations of electroporation and HMT. All images 
at 10x objective, except 20x objective for (c). (a) HMT/E. (b) Positive control for HMT/E (DNA only). (c) 
E/HMT. (d) Positive control for E/HMT. (e) HMT. 
 
(a) 
(e) 
(d) (c) 
(b) 
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A.7.2 Increasing Histone:DNA Ratio 
A couple of suggestions were brought up for modifying the HMT/E procedure. 
One of those suggestions was increasing the histone:DNA ratio, in the hopes that more 
carrier histones would increase the efficiency of transfection. The histone ratio was 
increased to 4:1, for 24.4 µg histones to 6.5 µg ColorfulCell. Cells were otherwise 
transfected and observed post-transfection in the same manner as described for HMT/E in 
the previous set of experiments; representative fluorescence images can be seen in Figure 
A.11. Contrary to expectations, the efficiency of gene delivery actually dropped. Very 
few cells were to be found among the HMT/E cells (Figure A.11(a)), as compared to the 
positive control (Figure A.11(b)). Calculated efficiencies were 0.9%, compared to the 
positive control’s 5.2%. 
          
Figure A.11. Representative fluorescence images of HMT/E with a 4:1 histone:DNA ratio. All images at 
10x objective. (a) HMT/E. (b) Positive control for HMT/E (DNA only). 
 
A.7.3 Increasing Histone – DNA Complexation Time 
Another possible fix posited was increasing the time allowed for the histones to 
complex with the DNA payload. The initial complexation time of 15 mins was derived 
(a) (b) 
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from Wagstaff et al., but longer complexation times were hypothesized to possibly give 
more time for the histones to bind to the DNA via electrostatic interactions. Incubation 
times of 4 h, 8 h, and 24 h were tested. A couple of other steps in the method were 
modified as well. When the histone-DNA complexes were added to the cells and 
incubated for 1 h, the incubation occurred under shaking conditions in a 6-well plate at 
100 rpm. This was hoped to aid in helping the cells maintain oxygen uptake. Post-
electroporation, the cells in a T25 suspension flask were also incubated on an orbital 
shaker for the same reason. 
Figure A.12 shows representative fluorescent images of each of the different 
timepoints, compared to the positive control of DNA only. As can be seen, across Figures 
A.12(b), (c), and (d), there really appears to be no difference in the number of fluorescent 
cells between the different time points. 
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Figure A.12. Representative fluorescence images of HMT/E with increased histone – DNA complexation 
times. All images at 10x objective. (a) Positive control for HMT/E (DNA only). (b) HMT/E with 4 h 
complexation time. (c) HMT/E with 8 h complexation time. (d) HMT/E with 24 h complexation time. 
 
These experiments appeared to indicate that, while HMT worked reasonably well 
for an adherent cell line like HEK 293, that success apparently did not translate to 
suspension cells. It also did not appear to have any sort of additive effect when combined 
with electroporation; thus, the latter was used as the gene delivery mechanism of choice 
going forward. 
(a) 
(d) (c) 
(b) 
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A.8 Summary 
In order to obtain histones for histone-mediated transfection studies, the plasmid 
pET29a-YS14 was transformed into E. coli BL21(DE3) and expressed via IPTG 
induction. The culture was lysed via sonication, and expression of histones was 
confirmed by running lysate of induced cells with lysate of un-induced cells on an SDS-
PAGE gel. Induced cell lysate was subsequently centrifuged and purified by FPLC. 
Relevant fractions from the chromatogram were run on an SDS-PAGE gel, and one 
fraction corresponding to an elution peak at 500 mM imidazole produced bands of 
expected size with few other detectable bands. The identities of the proteins in the 
fraction were confirmed by mass spectrometry to be histones H2A, H2B, H3, and H4. 
The fraction was buffer-exchanged to PBS by ultrafiltration, SDS-PAGE was used to 
confirm that proteins were not lost in ultrafiltration, and a BCA assay was used to 
estimate a protein concentration of 371.6 ng/µL. 
Pilot HMT studies in HEK 293 cells were carried out using mTFP1-C1 and 
purified histones. Some cells were successfully transfected, with a trend of increasing 
number of cells transfected as histone mass was increased. Decreasing DNA mass did not 
seem to show a discernible trend in terms of increasing or decreasing number of cells 
transfected. In CHOZN GS-/-, combinations of HMT and/or electroporation were 
explored, leading to the general observations that histones did not have an effect on 
electroporation efficiencies, while HMT alone did not produce any transfected cells. 
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